Drug Patents owned by Novo

1. Drug name - MACRILEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(a month ago)

CN1736985A NOVO Growth Hormone Secretagogues
Sep, 2007

(15 years ago)

CN1232507C NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

CN1431998A NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

IN224552B NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

IN200201550P3 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

EP1524272B1 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

EP1524272A1 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

EP1344773B1 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

EP1344773A1 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

EP1289951B1 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

EP1289951A1 NOVO Growth Hormone Secretagogues
Jun, 2021

(1 year, 3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds Oct, 2027

(5 years from now)

Drugs and Companies using MACIMORELIN ACETATE ingredient

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE/POUCH FOR SOLUTION;ORAL Prescription

2. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8579869 NOVO Needle mounting system and a method for mounting a needle assembly Jun, 2023

(9 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display Oct, 2025

(3 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen Aug, 2026

(3 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display Feb, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism Sep, 2027

(5 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen Feb, 2032

(9 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

3. Drug name - RYBELSUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec, 2031

(9 years from now)

US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec, 2031

(9 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid Dec, 2031

(9 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof Mar, 2033

(10 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds May, 2034

(11 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

4. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(a month ago)

CN1232470A NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1951965B NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1951965A NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN100569798C NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1271086C NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1740198A NOVO Glp-1 Derivatives
Aug, 2017

(5 years ago)

EP1840134A3 NOVO Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775B1 NOVO Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1840134A2 NOVO Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1840134B1 NOVO Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775A1 NOVO Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1062240B1 NOVO N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061946A1 NOVO Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1060191B1 NOVO Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1062240A1 NOVO N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061946B1 NOVO Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1060191A1 NOVO Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1061947A1 NOVO Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP1061947B1 NOVO Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP944648A1 NOVO Glp-1 Derivatives
Aug, 2022

(a month ago)

EP944648B1 NOVO Glp-1 Derivatives
Aug, 2022

(a month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1 Dec, 2022

(2 months from now)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs Feb, 2023

(4 months from now)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly Jun, 2023

(9 months from now)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly Dec, 2023

(1 year, 3 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly Nov, 2024

(2 years from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display Oct, 2025

(3 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Feb, 2026

(3 years from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display Apr, 2026

(3 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism Jul, 2026

(3 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism Jul, 2026

(3 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen Aug, 2026

(3 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jan, 2027

(4 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jan, 2027

(4 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jan, 2027

(4 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen Feb, 2027

(4 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display Feb, 2027

(4 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display Aug, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism Sep, 2027

(5 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism Mar, 2028

(5 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen Feb, 2032

(9 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen Aug, 2032

(9 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions Jan, 2037

(14 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions Jul, 2037

(14 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

5. Drug name - WEGOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof Aug, 2038

(15 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.25MG/0.5ML (0.25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
0.5MG/0.5ML (0.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1MG/0.5ML (1MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1.7MG/0.75ML (1.7MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription
2.4MG/0.75ML (2.4MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.